Forecast of the Day: Pfizer’s Immunology Drugs Revenue
The first interim efficacy analysis of Phase 2/3 clinical trial evaluating Pfizer and BioNTech’s Covid-19 vaccine candidate showed it to be more than 90% effective seven days after the second dose in preventing infection in participants with no evidence of prior SARS-CoV-2 infection. An emergency use authorization (EUA) application will be made after the required safety milestone is achieved, expected to occur in the third week of November.
Click here for the full Trefis coverage of Pfizer
- What Factors Will Drive Pfizer’s Q1 Performance?
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
Looking for a balanced portfolio to invest in? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams